Evidence map›Paper›PMID 33574218›Full record

ArticleBlood cancer journal2021

Reduced CXCL4/PF4 expression as a driver of increased human hematopoietic stem and progenitor cell proliferation in polycythemia vera.

Fabienne Meier-Abt, Witold E Wolski, Ge Tan, Sandra Kummer, Sabine Amon, Markus G Manz, Ruedi Aebersold, Alexandre P A Theocharides

Open access · goldAbstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood cancer journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Journal of proteome research · 2023
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Fabienne Meier-AbtDepartment of Medical Oncology and Hematology, University Hospital Zurich and University of Zurich, Zurich, Switzerland. fabienne.meier-abt@usz.ch.ORCID 0000-0001-5337-6210
Witold E WolskiFunctional Genomics Center Zurich, University and ETH Zurich, Zurich, Switzerland.
Ge TanFunctional Genomics Center Zurich, University and ETH Zurich, Zurich, Switzerland.ORCID 0000-0003-0026-8739
Sandra KummerDepartment of Medical Oncology and Hematology, University Hospital Zurich and University of Zurich, Zurich, Switzerland.
Sabine AmonDepartment of Biology, Institute of Molecular Systems Biology, ETH Zurich, Zurich, Switzerland.
Markus G Manz *Department of Medical Oncology and Hematology, University Hospital Zurich and University of Zurich, Zurich, Switzerland.
Ruedi Aebersold *Department of Biology, Institute of Molecular Systems Biology, ETH Zurich, Zurich, Switzerland.
Alexandre P A Theocharides *Department of Medical Oncology and Hematology, University Hospital Zurich and University of Zurich, Zurich, Switzerland.
University of Zurich · CHETH Zurich · CHSIB Swiss Institute of Bioinformatics · CH

Funding

Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (Swiss National Science Foundation) 3100A0-688 107679
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Cell ProliferationDown-RegulationAntineoplastic AgentsHematopoietic Stem CellsHumansHydroxyureaPlatelet Factor 4Polycythemia VeraTranscriptomeAntineoplastic AgentsHydroxyureaPF4 protein, humanPlatelet Factor 4

Identifiers

PMID33574218
PMCPMC7878875
OpenAlexW3126785959

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.